Table 4. Sustained virologic response rates (95% confidence intervals) in participants with HCV GT1 infection who initiated direct-acting antiviral treatmenta.
| Evaluable Population | Per-Protocol Population | |||
|---|---|---|---|---|
| No. of Participants Achieving SVR, % (95% CI) |
n | No. of Participants Achieving SVR, % (95% CI) |
n | |
| All participants | 355 83.92 (81–87) |
423 | 343 84.69 (81–88) |
405 |
| 8-week treatment | 15 83.33 (59–96) |
18 | 14 82.35 (57–96) |
17 |
| 12-week treatment | 261 84.74 (80–89) |
308 | 260 85.25 (81–89) |
305 |
| 24-week treatment | 68 82.93 (73–90) |
82 | 68 82.93 (73–90) |
82 |
| SVR by subgroup | ||||
| Female | 153 85.00 (79–90) |
180 | 148 84.06 (79–90) |
174 |
| Male | 202 83.13 (78–88) |
243 | 195 84.42 (79–89) |
231 |
| Cirrhosis | 154 78.17 (72–84) |
197 | 149 78.42 (72–84) |
190 |
| No cirrhosis | 201 88.94 (84–93) |
226 | 194 90.23 (85–94) |
215 |
| Black | 82 92.13 (84–97) |
89 | 79 94.05 (87–98) |
84 |
| Non-black | 273 81.74 (77–86) |
334 | 264 82.24 (78–86) |
321 |
| Treatment-experienced | 104 82.54 (75–89) |
126 | 100 82.64 (75–89) |
121 |
| Treatment-naive | 251 84.51 (80–88) |
297 | 243 85.56 (81–89) |
284 |
| Platelet count ≥100,000/μL | 220 88.71 (84–92) |
248 | 211 89.79 (85–93) |
235 |
| Platelet count <100,000/μL | 86 74.78 (66–82) |
115 | 83 74.45 (66–83) |
110 |
CI, confidence interval; DAA, direct-acting antiviral; GT, genotype; HCV, hepatitis C virus; SVR, sustained virologic response.
aSVR was estimated among participants with available SVR measurements.